Guangzhou Manjing Biomedicine Technology

Guangzhou Manjing Biomedicine Technology is a clinical-stage biotechnology company based in Guangzhou, China, specializing in the development of innovative small molecule drugs for metabolic diseases. The company's primary focus is on addressing the unmet medical needs of patients with chronic conditions, particularly hyperuricemia and gout. Its lead candidate, MJ001, is a potent and selective URAT1 inhibitor currently in clinical development to evaluate its efficacy in lowering serum uric acid levels. Manjing Biomedicine leverages its expertise in medicinal chemistry to build a pipeline of therapies aimed at improving the quality of life for patients with metabolic disorders. The company is headquartered in the Guangzhou International Bio Island and has received backing from several prominent Chinese investment firms. It maintains strong ties with academic institutions like Sun Yat-sen University to drive its research and development efforts.